Maze Therapeutics officer plans sale of 9,705 shares

Maze Therapeutics, Inc. (MAZE) has a notice from officer Harold Bernstein under Rule 144 indicating an intention to sell up to 9,705 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 4, 2026, on NASDAQ.

Available on EDGAR 09/04/2026 - 04:34 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) has a notice from officer Harold Bernstein under Rule 144 indicating an intention to sell up to 9,705 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 4, 2026, on NASDAQ.

The shares to be sold were acquired as Restricted Stock Units from the issuer on September 1, 2026. Bernstein also reports several common stock sales during the prior three months, including transactions made pursuant to a Rule 10b5-1 trading plan.

Key Figures

Shares proposed to be sold: 9,705 shares Aggregate market value of proposed sale: $251,068.35 Recent sale on September 1, 2026 (10b5-1): 16,141 shares for $425,512.27 +3 more

6 metrics

Shares proposed to be sold 9,705 shares Common stock covered by the Rule 144 notice through Morgan Stanley Smith Barney LLC

Aggregate market value of proposed sale $251,068.35 Aggregate market value for the 9,705 Maze Therapeutics shares in the new notice

Recent sale on September 1, 2026 (10b5-1) 16,141 shares for $425,512.27 Common stock sale labeled as 10b5-1 Sales for Harold Bernstein

Additional sale on September 1, 2026 10,295 shares for $270,110.94 Common stock sale by Harold Bernstein reported in past three months

Sale on August 13, 2026 (10b5-1) 16,142 shares for $445,620.09 Common stock sale labeled as 10b5-1 Sales for Harold Bernstein

Sale on July 1, 2026 (10b5-1) 14,609 shares for $436,864.00 Common stock sale labeled as 10b5-1 Sales for Harold Bernstein

Key Terms

Rule 144, 10b5-1, Restricted Stock Units, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Restricted Stock Units financial

"Common | 09/01/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 9705 | 251068.35"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for MAZE by Harold Bernstein disclose?

It discloses that officer Harold Bernstein intends to sell up to 9,705 shares of Maze Therapeutics common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with the contemplated sale date of September 4, 2026 on NASDAQ.

How many MAZE shares does Harold Bernstein plan to sell in this Form 144?

The notice covers a proposed sale of up to 9,705 shares of Maze Therapeutics common stock, with an indicated aggregate market value of $251,068.35 for these shares.

How were the MAZE shares in the new Form 144 acquired by Harold Bernstein?

The 9,705 shares covered by the notice were acquired as Restricted Stock Units from Maze Therapeutics, with an acquisition date of September 1, 2026 and the issuer listed as the source.

What MAZE stock sales has Harold Bernstein reported in the past three months?

Reported past three-month sales include 16,141 shares for $425,512.27 and 10,295 shares for $270,110.94 on September 1, 2026; 16,142 shares for $445,620.09 on August 13, 2026; and 14,609 shares for $436,864.00 on July 1, 2026.

Does the MAZE Form 144 mention a Rule 10b5-1 trading plan?

Yes. Several of the sales during the past three months are labeled as 10b5-1 Sales for Harold Bernstein, indicating they were executed under a pre-established Rule 10b5-1 trading plan.

Who is the broker for the MAZE shares in Harold Bernstein’s Form 144?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, New York, which is identified for the planned sale of 9,705 shares of Maze Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002050172
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 Oyster Point Blvd South San Francisco CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	HAROLD BERNSTEIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9705	251068.35	55549168	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Restricted Stock Units	Issuer			9705	09/01/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd South San Francisco CA 94080	Common	09/01/2026	16141	425512.27
HAROLD BERNSTEIN 171 Oyster Point Blvd South San Francisco CA 94080	Common	09/01/2026	10295	270110.94
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd South San Francisco CA 94080	Common	08/13/2026	16142	445620.09
10b5-1 Sales for HAROLD BERNSTEIN 171 Oyster Point Blvd South San Francisco CA 94080	Common	07/01/2026	14609	436864.00

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Harold Bernstein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)